share_log

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K:重大事件
美股SEC公告 ·  10/22 08:03

Moomoo AI 已提取核心訊息

On October 18, 2024, Mangoceuticals, Inc., a company specializing in men's health and wellness products, entered into a material definitive agreement with Cohen Enterprises, Inc. The agreement involves a $150,000 promissory note, known as the Cohen Note, to consolidate two previous loans from Cohen Enterprises totaling the same amount. The note, accruing interest at 8% per annum, is due by January 2, 2025, or earlier upon certain conditions. Additionally, Mangoceuticals announced on October 22, 2024, that its Board of Directors is exploring strategic alternatives to enhance shareholder value, which may include mergers, acquisitions, or other significant business transactions. The company emphasized that there is no set timeline for this strategic review and no assurance of any particular outcome. Mangoceuticals, also known as MangoRx, operates a telemedicine platform offering various men's wellness services and products, with a focus on areas such as erectile dysfunction, hair growth, hormone replacement therapies, and weight management.
On October 18, 2024, Mangoceuticals, Inc., a company specializing in men's health and wellness products, entered into a material definitive agreement with Cohen Enterprises, Inc. The agreement involves a $150,000 promissory note, known as the Cohen Note, to consolidate two previous loans from Cohen Enterprises totaling the same amount. The note, accruing interest at 8% per annum, is due by January 2, 2025, or earlier upon certain conditions. Additionally, Mangoceuticals announced on October 22, 2024, that its Board of Directors is exploring strategic alternatives to enhance shareholder value, which may include mergers, acquisitions, or other significant business transactions. The company emphasized that there is no set timeline for this strategic review and no assurance of any particular outcome. Mangoceuticals, also known as MangoRx, operates a telemedicine platform offering various men's wellness services and products, with a focus on areas such as erectile dysfunction, hair growth, hormone replacement therapies, and weight management.
2024年10月18日,專注於男性健康和健康產品的Mangoceuticals, Inc.與Cohen Enterprises, Inc.簽署了一份重大決策協議。該協議涉及一份價值15萬美元的期票,被稱爲Cohen Note,用於整合Cohen Enterprises之前總額相同的兩筆貸款。該票據年息率爲8%,於2025年1月2日到期,或在特定條件下提前到期。此外,Mangoceuticals於2024年10月22日宣佈,其董事會正在探討提升股東價值的戰略選擇,可能包括併購、收購或其他重大業務交易。該公司強調此戰略審查沒有明確時間表,也不能保證特定結果。被稱爲MangoRx的Mangoceuticals經營着一個提供各種男性健康服務和產品的遠程醫療平台,重點關注領域包括勃起功能障礙、頭髮生長、激素替代療法和體重管理。
2024年10月18日,專注於男性健康和健康產品的Mangoceuticals, Inc.與Cohen Enterprises, Inc.簽署了一份重大決策協議。該協議涉及一份價值15萬美元的期票,被稱爲Cohen Note,用於整合Cohen Enterprises之前總額相同的兩筆貸款。該票據年息率爲8%,於2025年1月2日到期,或在特定條件下提前到期。此外,Mangoceuticals於2024年10月22日宣佈,其董事會正在探討提升股東價值的戰略選擇,可能包括併購、收購或其他重大業務交易。該公司強調此戰略審查沒有明確時間表,也不能保證特定結果。被稱爲MangoRx的Mangoceuticals經營着一個提供各種男性健康服務和產品的遠程醫療平台,重點關注領域包括勃起功能障礙、頭髮生長、激素替代療法和體重管理。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息